A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Condition(s) studied

Investigational drug(s) / intervention(s)

ANS014004: Varying doses of ANS014004

Study summary

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

Eligibility

Primary outcome measure(s)

• Incidence of Adverse Events (AEs) — From the time of first dose to 28 days post last dose of ANS014004
  Number of patients with adverse events by system organ class and preferred term
• Incidence of Serious Adverse Events (SAEs) — From time of first dose to 28 days post last dose of ANS014004
  Number of patients with serious adverse events by system organ class and preferred term
• Incidence of dose-limiting toxicities (DLT) as defined in the protocol — From time of first dose of ANS014004 to end of DLT period (approximately 30 days)
  Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
• Incidence of baseline laboratory finding, ECG and vital signs changes — From time of first dose to 28 days post last dose of ANS014004
  measured by laboratory and vital sign variables over time including change from
• Proportion of patients with radiological response (ORR) — From date of first dose of ANS014004 until progression, or the last evaluable assessment in the absence of progression （approximately 2 years)）
  Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1

Trial sites (15)

More Avistone Biotechnology Co., Ltd. trials in the USA

Other trials for the same condition